You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
一圖看懂北海康成(1228.HK)IPO
格隆匯 11-30 16:23

今日,專注於罕見病領域的北海康成開始於港交所招股,每股發售股份12.18港幣,一手入場費12303港幣,招股期為11月30日至12月3日,聯席保薦人為Morgan Stanley及Jefferies。招股書顯示,上市前,藥明康德為北海康成最大外部股東,持有10.97%股份。

據Frost&Sullivan數據預計,罕見病將會影響全球3.5%至5.9%的人口,全球罕見病藥物市場規模也將由2020年的1351億美元增至2030年的3833億美元,年複合增長率為11%。其中,我國罕見病藥物市場預計將由2020年13億美元高速增至2030年259億美元,年複合增長率高達34.5%,遠高於美國及其他地區增速。

北海康成成立於2012年,一直專注佈局於罕見病領域,致力於研究、開發及商業化生物科技療法,針對最常見的罕見病以及罕見的腫瘤適應症來發展其產品管線。在成立不到10年的時間裏,北海康成通過自主研發及合作的方式,擁有涵蓋13個具有極大市場潛力的產品管線,其中就包括3個已成功上市產品。其中,其首款商業化罕見病產品Hunterase®(CAN101)是中國第一個且唯一獲得批准上市治療MPS II的ERT藥物。

身處於我國罕見病領域第一梯隊,北海康成不同於大多數創新藥公司,其3款商業化上市產品已在為公司帶來持續增長的收入。據招股書顯示,公司2019年營收為146.9萬元,並於2020年增至1203.2萬元,同比增長719%;2021年上半年達1219.2萬元,同比增長527%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account